Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 200-861-4 | CAS number: 75-33-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Specific investigations: other studies
Administrative data
Link to relevant study record(s)
- Endpoint:
- specific investigations: other studies
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: Study well documented, meets generally accepted scientific principles, acceptable for assessment
- Qualifier:
- no guideline available
- Principles of method if other than guideline:
- To evaluate the degree of sensory irritation elicited by propane-2-thiol when administered by inhalation to mice (Y. Alarie (1966) Arch. Environ. Health, 13:433-449)
- GLP compliance:
- yes
- Type of method:
- in vivo
- Endpoint addressed:
- respiratory irritation
- Species:
- mouse
- Strain:
- CD-1
- Sex:
- male
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Inc.
- Age at study initiation: no data
- Weight at study initiation: 20-25 g
- Fasting period before study:
- Housing: group housed in stainless-steel wiremesh cages
- Diet (ad libitum): Purina Lab Chow #5001
- Water (ad libitum): tap water
- Acclimation period: >= 7 days
ENVIRONMENTAL CONDITIONS
- Temperature: 70 +/- 4°F
- Humidity (%): 40-60
- Air changes (per hr): no data
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- inhalation: vapour
- Vehicle:
- unchanged (no vehicle)
- Details on exposure:
- GENERATION OF TEST ATMOSPHERE / CHAMBER DESCRIPTION
- Exposure apparatus: head only chambers with attached plethysmographs
- Method of holding animals in test chamber: each mouse was placed in a plethysmograph with its head projecting into the control plastic exposure core which has a volume of approximately 750 mls
- Rate of air: 7.5 ml/min
- System of generating vapors: water-jacketed counter-flow column maintained at ca. 80°F
- Treatment of exhaust air: no data
- Temperature, humidity in air chamber: 75 +/- 3°F, 50-70%
TEST ATMOSPHERE
- Brief description of analytical method used: Total hydrocarbon analysis
- Samples taken from breathing zone: no data
TEST ATMOSPHERE
- Brief description of analytical method used:
- Samples taken from breathing zone: yes/no
VEHICLE (if applicable)
- Justification for use and choice of vehicle:
- Composition of vehicle:
- Type and concentration of dispersant aid (if powder):
- Concentration of test material in vehicle:
- Lot/batch no. of vehicle (if required):
- Purity of vehicle: - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Total hydrocarbon analysis
- Duration of treatment / exposure:
- 1 min
- Remarks:
- Doses / Concentrations:
24.55 mg/l
Basis:
nominal conc. - Remarks:
- Doses / Concentrations:
36.07 mg/l
Basis:
analytical conc. - No. of animals per sex per dose:
- 4
- Control animals:
- other: A control respiratory pattern was first established during which the animals were exposed to room air
- Examinations:
- The animals were sequentially exposed first to the the test substance for one (1) minute, next to room air for ten (10) minutes, and to a second one (1) minute exposure to the test material, the respiratory patterns of the animals was continuously monitored. Following the second exposure, animals were monitored for a minimum of five (5) minutes or until recovery while breathing room air.
- Positive control:
- none
- Details on results:
- No upper airway irritancy was observed in mice exposed 1 min to 36.07 mg/l propane-2-thiol
- Conclusions:
- No upper airway irritancy was observed in mice exposed 1 min to 36.07 mg/l propane-2-thiol.
- Endpoint:
- biochemical or cellular interactions
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Rationale for reliability incl. deficiencies:
- other: data from iCSS CompTox Dashboard. Data Quality 100%. Data manually curated with highest confidence
- Principles of method if other than guideline:
- Using a high-throughput robotic screening system, IPM was assessed for its potential to disrupt biological pathways (DNA binding, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity.
- Type of method:
- in vitro
- Specific details on test material used for the study:
- Sample: Tox21_201170
- Vehicle:
- DMSO
- Remarks:
- 0.001 to 100µM
- Details on study design:
- See enclosed excel file
- Details on results:
- 113 assays were performed, dimethyl disulphide did not induce a positive response. Therefore, there is no evidence that dimethyl disulphide could interfere with the expression of the screened genes.
- Executive summary:
IPM was evaluated in the ToxCast & Tox21 High-throughput Assays to assess its potential to disrupt biological pathways (DNA binding, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 113 assays were performed at concentrations ranging from 0.001 to 100 µM. Cytotoxicity was assessed in 18 assays, and no cytotoxicity was observed. IPM did not induce a positive response in any assay. Therefore, there is no evidence that IPM could interfere with the expression of the screened genes .
- Endpoint:
- biochemical or cellular interactions
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 2 (reliable with restrictions)
- Principles of method if other than guideline:
- The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities
- Type of method:
- in vivo
- Specific details on test material used for the study:
- PubChem CID: 6364
PubChem SID: 17388960 and 144208368 - Details on results:
- 299 bioassays with 311 bioactivity outcomes were retrieved from the PubChem BioAssay data base. IPM was inactive in 299 bioassays, inconclusive in 11 bioassays and 1 was unspecified.
- Executive summary:
The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities. 299 bioassays with 311 bioactivity outcomes were retrieved . IPM was inactive in 299 bioassays, inconclusive in 11 bioassays and 1 was unspecified. IPM had no activity on cell viability assays, no agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR) signaling pathways.
Referenceopen allclose all
113 assays were performed, all results are displayed in the enclosed excel file.
IPM did not induce a positive response (see attached figure and table).
Intended Target Family |
Assay Component Endpoint Name |
hitCall |
AC50 |
modlGa |
modlTp |
dna binding |
TOX21_AhR_LUC_Agonist |
Inactive |
0 |
0 |
|
background measurement |
TOX21_AR_BLA_Agonist_ch1 |
Inactive |
16.4 |
0 |
0 |
background measurement |
TOX21_AR_BLA_Agonist_ch2 |
Inactive |
> 100 |
0 |
0 |
nuclear receptor |
TOX21_AR_BLA_Agonist_ratio |
Inactive |
29.1 |
0 |
0 |
background measurement |
TOX21_AR_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AR_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_AR_BLA_Antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_AR_BLA_Antagonist_viability |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_AR_LUC_MDAKB2_Agonist |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_AR_LUC_MDAKB2_Antagonist |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ARE_BLA_Agonist_ch1 |
Inactive |
>100 |
1.21418274 |
0.35134189 |
background measurement |
TOX21_ARE_BLA_Agonist_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_ARE_BLA_agonist_ratio |
Inactive |
>100 |
1.46366796 |
0.25884231 |
cell cycle |
TOX21_ARE_BLA_agonist_viability |
Inactive |
>100 |
0 |
0 |
cyp |
TOX21_Aromatase_Inhibition |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEK293_Cell_blue |
Inactive |
21.3 |
1.32892837 |
0.01630053 |
background measurement |
TOX21_AutoFluor_HEK293_Cell_green |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEK293_Cell_red |
Inactive |
49.5 |
1.6943105 |
0.03501426 |
background measurement |
TOX21_AutoFluor_HEK293_Media_blue |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEK293_Media_green |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEK293_Media_red |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Cell_blue |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Cell_green |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Cell_red |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Media_blue |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Media_green |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_AutoFluor_HEPG2_Media_red |
Inactive |
>100 |
0 |
0 |
hydrolase |
TOX21_ELG1_LUC_Agonist |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ERa_BLA_Agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ERa_BLA_Agonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_ERa_BLA_Agonist_ratio |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ERa_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ERa_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_ERa_BLA_Antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_ERa_BLA_Antagonist_viability |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_ERa_LUC_BG1_Agonist |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_ERa_LUC_BG1_Antagonist |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ESRE_BLA_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_ESRE_BLA_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_ESRE_BLA_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_ESRE_BLA_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_FXR_BLA_agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_FXR_BLA_agonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_FXR_BLA_agonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_FXR_BLA_agonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_FXR_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_FXR_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_FXR_BLA_antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_FXR_BLA_antagonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_GR_BLA_Agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_GR_BLA_Agonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_GR_BLA_Agonist_ratio |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_GR_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_GR_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_GR_BLA_Antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_GR_BLA_Antagonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_HSE_BLA_agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_HSE_BLA_agonist_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_HSE_BLA_agonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_HSE_BLA_agonist_viability |
Inactive |
>100 |
0 |
0 |
cell morphology |
TOX21_MMP_ratio_down |
Inactive |
>100 |
0 |
0 |
cell morphology |
TOX21_MMP_ratio_up |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_MMP_viability |
Inactive |
0.012 |
-1.92209299 |
0.15384784 |
background measurement |
TOX21_NFkB_BLA_agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_NFkB_BLA_agonist_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_NFkB_BLA_agonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_NFkB_BLA_agonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p1_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p1_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_p53_BLA_p1_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_p53_BLA_p1_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p2_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p2_ch2 |
Inactive |
73.7 |
1.86746683 |
0.37908609 |
dna binding |
TOX21_p53_BLA_p2_ratio |
Inactive |
66.8 |
1.8244565 |
0.17919924 |
cell cycle |
TOX21_p53_BLA_p2_viability |
Inactive |
0.0000769 |
-4.11432278 |
0.64304762 |
background measurement |
TOX21_p53_BLA_p3_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p3_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_p53_BLA_p3_ratio |
Inactive |
0.117 |
-0.93246372 |
0.19038952 |
cell cycle |
TOX21_p53_BLA_p3_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p4_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p4_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_p53_BLA_p4_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_p53_BLA_p4_viability |
Inactive |
0.0887 |
-1.05197313 |
0.36166764 |
background measurement |
TOX21_p53_BLA_p5_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_p53_BLA_p5_ch2 |
Inactive |
>100 |
0 |
0 |
dna binding |
TOX21_p53_BLA_p5_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_p53_BLA_p5_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARd_BLA_agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARd_BLA_agonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_PPARd_BLA_agonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_PPARd_BLA_Agonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARd_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARd_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_PPARd_BLA_antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_PPARd_BLA_antagonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARg_BLA_Agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARg_BLA_Agonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_PPARg_BLA_Agonist_ratio |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARg_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_PPARg_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_PPARg_BLA_antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_PPARg_BLA_antagonist_viability |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_TR_LUC_GH3_Agonist |
Inactive |
>100 |
0 |
0 |
nuclear receptor |
TOX21_TR_LUC_GH3_Antagonist |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_VDR_BLA_agonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_VDR_BLA_agonist_ch2 |
Inactive |
>100 |
0 |
0 |
cyp |
TOX21_VDR_BLA_agonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_VDR_BLA_Agonist_viability |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_VDR_BLA_Antagonist_ch1 |
Inactive |
>100 |
0 |
0 |
background measurement |
TOX21_VDR_BLA_Antagonist_ch2 |
Inactive |
>100 |
0 |
0 |
cyp |
TOX21_VDR_BLA_antagonist_ratio |
Inactive |
>100 |
0 |
0 |
cell cycle |
TOX21_VDR_BLA_antagonist_viability |
Inactive |
>100 |
0 |
0 |
null |
undefined |
Inactive |
>100 |
0 |
0 |
The list of all the assays performed is displayed in the enclosed excel file.
Description of key information
Propane-2 -thiol is not a respiratory tract irritant after an acute inhalation exposure (Pence, 1983).
Propane-2 -thiol was evaluated in the ToxCast & Tox21 High-throughput Assays (US EPA, 2017) to assess its potential to disrupt biological pathways (DNA binding, nuclear receptor (non-steroidal and steroidal), cell cycle, cytochrome P450, hydrolase and cell morphology) that may result in toxicity. 113 assays were performed at concentrations ranging from 0.001 to 100 µM. Cytotoxicity was assessed in 18 assays, and no cytotoxicity was observed. IPM did not induce a positive response in any assay. Therefore, there is no evidence that IPM could interfere with the expression of the screened genes .
The PubChem BioAssay database was searched for chemogenomic, medicinal chemistry and functional genomics biological activities with propane-2 -thiol (NCBI, 2017). 299 bioassays with 311 bioactivity outcomes were retrieved . Propane-2 -thiol was inactive in 299 bioassays, inconclusive in 11 bioassays and 1 was unspecified. Propane-2 -thiol had no activity on cell viability assays, no agonist and/or antagonist activities on the peroxisome proliferator-activated receptor alpha (PPARa), delta (PPARd) and gamma (PPARg), androgen receptor (AR), estrogen receptor alpha (ER-alpha), thyroid receptor (TR) and glucocorticoid receptor (GR) signaling pathways.
Additional information
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.